Z-LVG-CHN2

Cat. No.:	HY-108137		
CAS No.:	119670-30-3	3	
Molecular Formula:	$C_{22}H_{31}N_5O_5$		
Molecular Weight:	445.51		
Target:	Cathepsin;	HSV; SAR	S-CoV
Pathway:	Metabolic E	nzyme/P	rotease; Anti-infection
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (224.46 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.2446 mL	11.2231 mL	22.4462 mL		
		5 mM	0.4489 mL	2.2446 mL	4.4892 mL		
		10 mM	0.2245 mL	1.1223 mL	2.2446 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.61 mM); Suspended solution; Need ultrasonic						
	 Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.61 mM); Suspended solution; Need ultrasonic 						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.61 mM); Clear solution						

BIOLOGICAL ACTIVITY				
Description	Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC ₅₀ =190 nM) via inhibition of SARS-COV-2 3CL pro protease ^[3] .			
IC ₅₀ & Target	EC50: 190 nM (SAR-COV-2) ^[3]			
In Vitro	Z-LVG-CHN2 (0-10 μM; pre-treated for 16 h) inhibits antiviral activities in a discernable dose-dependent manner in Vero E6			

C O

M^{*}_{≥N}



cells by designed to cap MCE has not independe Cell Viability Assay ^[3]	pture multicycle replication, exhibiting an EC ₅₀ value of 0.19 μ M ^[1] . ently confirmed the accuracy of these methods. They are for reference only.
Cell Line:	Vero E6 cells
Concentration:	0.001 μΜ, 0.003 μΜ, 0.1 μΜ, 0.3 μΜ, 1 μΜ, 2.5 μΜ
Incubation Time:	Pre-treated for 16 h and then cultured for 24 hours
Result:	Inhibited SARS-COV-2 virus replication in a dose-dependent manner.

CUSTOMER VALIDATION

- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.
- Sci Rep. 2022 Jul 16;12(1):12197.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. R L Mellgren, et al. Inhibition of growth of human TE2 and C-33A cells by the cell-permeant calpain inhibitor benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone. Exp Cell Res. 1994 Nov;215(1):164-71.

[2]. L Björck, et al. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol

[3]. Laura Riva, et al.A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. bioRxiv. 2020 Apr 17;2020.04.16.044016.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA